

B CELL DESIGN

Field of expertise

From an innovation resulting from the fundamental research of University of Limoges, B Cell Design conceive and produce chimeric monoclonals antibodies. Our technology is based on the spontaneous synthesis of IgA1 and IgG1 chimeric antibodies by patented transgenic mice. Our technology, faster and simpler than the other existing technologies is a breakthrough particularly for the production of IgA1 antibodies.

Identity

B-cell Design is a spin-off of University of Limoges and has been created late 2007. Its head office is located in Limoges within the blood bank building in which B Cell Design occupy around 300 sqm. The leading team is constituted of Jean Sainte-Laudy, CEO, Armelle Cuvillier, CSO and Gael Champier, product manager. The scientific committee comprises Pr Michel Cogné (University of Limoges) and Pr Blaise Corthésy (University of Lausanne)

Activities and Products

B Cell Design has a double activity, one concerning research reagents and services, the other concerning immunotherapy. B Cell Design is capable of producing chimeric monomeric IgA1, dimeric IgA1, secretory IgA1, human secretory component and chimeric IgG1. B Cell Design services comprise mainly de novo antibodies production and transformation of antibodies by molecular biology technologies (humanization, transformation of murine antibodies to human antibodies or class change).

The mean delay for the production of de novo antibodies is around 4 to 6 months.

In immunotherapy, B Cell Design is particularly involved in infectious (RSV, HIV) and in oncology (lymphoma and colorectal cancers) but is also studying other therapeutic fields such as inflammation, food allergy and parasitic diseases. Recent scientific literature is in favour of the use of IgA in immunotherapy and the exceptional resistance of secretory IgAs to proteases open new possibilities of administration routes such as the topic administration of IgAs directly at the mucosal level (nose, bronchi, gut).

Partners

B Cell Design products are internationally available from two distributors (Medimabs in Montreal and P.A.R.I.S. in France) which added B Cell Design reagents and services in their catalogue.

These different developments have been supported by Oseo, the Region Limousin, and the ministry of research.

B Cell Design has also been financially supported by the French ANR for a research project concerning IgA and HIV.

Contacts

SAS B Cell Design

98 rue Legendre, 87000 Limoges.

www.b-cell-design.com

jslaudy@b-cell-design.com; armelle.cuvillier@b-cell-design.com; gael.champier@b-cell-design.com

IN VIVOLIM
biotechnology project in Limousin



b cell design